Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical outcome after implantation of the Tecnis Symfony extended range of vision IOL

Poster Details

First Author: A.Barisic CROATIA

Co Author(s):    N. Gabric   I. Dekaris   I. Romac              

Abstract Details


To evaluate 6 weeks clinical outcome in patients with bilateral implantation of the Tecnis Symfony Extended Range of Vision intraocular lens (IOL).


University Eye Hospital Svjetlost, Zagreb, Croatia.


Fourty six patients (92 eyes) were followed after cataract surgery or refractive lens exchange with bilateral implantation of the Tecnis Symfony IOL. Uncorrected distant visual acuity (UCDVA), uncorrected intermediate visual acuity (UCIVA) at 66 cm, uncorrected near visual acuity (UCNVA), spectacle independence, patient satisfaction and visual disturbances were measured. Follow up was at least 6 weeks.


We targeted emmetropy in dominant eye and mild myopia, up to -0,50 D in non dominant eye. Three patients sometimes wear reading glasses for small print. Three patients (four eyes) are scheduled for LASIK enhancement due to postoperative astigmatism more than 0,75 Dcyl. 93,5% of patients achieved binocular UCDVA 0.00 logMAR or better. Mean binocular UCIVA at 66 cm was 0.01 logMAR and UCNVA at patient’s preferred distance was also 0,01 logMAR. Night driving visual disturbances reported 6 of 46 patients (13%).


The 6 weeks data of the TECNIS® Symfony Extended Range of Vision IOL demonstrate extended range of vision with good uncorrected visual acuity for far and intermediate with low incidence of optical symptoms. Mild myopic shift up to -0.5 D in non dominant eye improves near vision without compromising distance and intermediate. Patients are highly satisfied and spectacle independent in everyday life.

Financial Disclosure:


Back to Poster listing